Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of View product.
$10,000.00
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment View product.
$10,000.00
Opdivo is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on View product.
$10,000.00
Tafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for mutated BRAF over wild-type.
$10,000.00
Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor cells, allowing the body’s immune View product.
$10,000.00
Zelboraf (vemurafenib; Roche/Chugai/Daiichi Sankyo) is an orally available agent that selectively targets the BRAF mutation. BRAF is part of the View product.
$10,000.00
This Market Spotlight report covers the Hereditary Angioedema market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory View product.
$2,995.00
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a View product.
$2,995.00
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, View product.
$2,995.00
This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming View product.
$2,995.00
This Market Spotlight report covers the insomnia market, comprising key pipeline and marketed drugs, clinical trials, regulatory events, patent information, View product.
$2,995.00
This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent View product.
$2,995.00
This Market Spotlight report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory View product.
$2,995.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease View product.
$2,995.00
This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, View product.
$2,995.00
This Market Spotlight report covers the Erectile Dysfunction market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory View product.
$2,995.00
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a novel, first-in-class potent analgesic that View product.
$10,000.00
Nucynta (tapentadol; Collegium Pharmaceutical) first gained US Food and Drug Administration (FDA) approval in November 2008 as an immediate-release formulation, View product.
$10,000.00
Raxatrigine (Biogen) is a peripherally and centrally acting agent that inhibits sodium channels in a state-dependent fashion. Raxatrigine shows selectivity View product.
$10,000.00